Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhen-Huan Cao

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi = Zhonghua Shiyan He Linchuang Bingduxue Zazhi = Chinese Journal of Experimental and Clinical Virology|December 25, 2008
[Study on T cell subsets in HIV/AIDS patients]Hai-Ying Li, Zhen-Huan Cao, Yun-Xia Ji, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|July 1, 2010
[Relationship between liver pathology and clinical characters in HBV carriers]Li-Na Ma, Zhi-Min He, Zhen-Huan Cao, et al.
Journal of Digestive Diseases|April 26, 2013
Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversionZhen Huan Cao, Li Na Ma, Hong Wei Zhang, et al.
World Journal of Gastrointestinal Oncology|December 16, 2024
Risk factors for hepatocellular carcinoma in cirrhosis: A comprehensive analysis from a decade-long studyDa-Qiong Zhou, Jiang-Yu Liu, Feng Zhao, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|January 9, 2016
[Efficacy of combination antiviral therapy following childbirth in pregnant HBV carriers receiving telbivudine for prevention of mother-to-child transmission]Jun-Feng Lu, Ya-Li Liu, Li-Na Ma, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|October 1, 2013
[Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients]Zhen-huan Cao, Li-na Ma, Ya-li Liu, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|April 3, 2012
[Efficacy of low-dose interferon therapy for treating chronic hepatitis C patients who cannot tolerate standard treatment]Zhen-huan Cao, Ya-li Liu, Yan-hong Zheng, et al.
Scandinavian Journal of Infectious Diseases|October 5, 2013
Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis CYa-Li Liu, Xiao-Fei Du, Xin-Yue Chen, et al.
Journal of Medical Virology|July 10, 2020
Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19Tong-Zeng Li, Zhen-Huan Cao, Yu Chen, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi = Zhonghua Shiyan He Linchuang Bingduxue Zazhi = Chinese Journal of Experimental and Clinical Virology|December 25, 2008
[Study on T cell subsets in HIV/AIDS patients]Hai-Ying Li, Zhen-Huan Cao, Yun-Xia Ji, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|July 1, 2010
[Relationship between liver pathology and clinical characters in HBV carriers]Li-Na Ma, Zhi-Min He, Zhen-Huan Cao, et al.
Journal of Digestive Diseases|April 26, 2013
Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversionZhen Huan Cao, Li Na Ma, Hong Wei Zhang, et al.
World Journal of Gastrointestinal Oncology|December 16, 2024
Risk factors for hepatocellular carcinoma in cirrhosis: A comprehensive analysis from a decade-long studyDa-Qiong Zhou, Jiang-Yu Liu, Feng Zhao, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|January 9, 2016
[Efficacy of combination antiviral therapy following childbirth in pregnant HBV carriers receiving telbivudine for prevention of mother-to-child transmission]Jun-Feng Lu, Ya-Li Liu, Li-Na Ma, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|October 1, 2013
[Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients]Zhen-huan Cao, Li-na Ma, Ya-li Liu, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|April 3, 2012
[Efficacy of low-dose interferon therapy for treating chronic hepatitis C patients who cannot tolerate standard treatment]Zhen-huan Cao, Ya-li Liu, Yan-hong Zheng, et al.
Scandinavian Journal of Infectious Diseases|October 5, 2013
Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis CYa-Li Liu, Xiao-Fei Du, Xin-Yue Chen, et al.
Journal of Medical Virology|July 10, 2020
Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19Tong-Zeng Li, Zhen-Huan Cao, Yu Chen, et al.
Pageof 1